TL;DR
This review critically examines the preclinical models used in photodynamic therapy (PDT) for cancer treatment. It highlights the limitations of traditional animal models and proposes that emerging organoid models offer a promising new avenue for more accurate and efficient PDT research, ultimately accelerating clinical translation.
What Problem Does This Paper Address?
Photodynamic therapy (PDT) is a promising, non-invasive cancer treatment that uses a photosensitizer, light, and oxygen to destroy tumor cells. However, despite its potential, the development of new photosensitizers, optimized therapeutic regimens, and a deeper understanding of PDT's efficacy and adverse effects are hampered by the limitations of current preclinical models. Translating findings from animal studies to human clinical trials has a notoriously low success rate (less than 8%), suggesting that existing models may not accurately recapitulate the complexity of human tumors and their microenvironments. This paper addresses the critical need for a comprehensive overview and evaluation of the diverse preclinical models employed in PDT research to guide future studies and improve the translation of PDT therapies to the clinic.
Methods
This paper is a narrative review, meaning it synthesizes existing research rather than presenting new experimental data. The authors conducted a systematic literature search across PubMed, Web of Science, and Scopus for original research articles published between 1997 and 2022. Their search focused on studies investigating PDT for tumor treatment using preclinical experimental and animal models. Inclusion criteria required original research articles on PDT for tumors, encompassing both in vitro and in vivo studies, with detailed methodological information. Exclusion criteria included non-original research, studies with insufficient data, and articles not in English. After screening over 1000 articles, 40 were selected for in-depth analysis, focusing on model construction, PDT parameters, observation indicators, and the advantages and disadvantages of each model.
Datasets
Not discussed in the paper. This is a review article, so it analyzes existing published data rather than using specific datasets for training or evaluation.
Key Insights and Ideas
- The "Valley of Death" in Cancer Research: The paper underscores the significant challenge of translating preclinical findings to clinical success, with animal models often failing to predict human responses accurately. This highlights the urgent need for more predictive preclinical models.
- Beyond Simple Tumor Killing: PDT's anti-tumor mechanisms are multifaceted, involving direct cell damage, immune stimulation, and vascular disruption. Effective preclinical models must be able to capture these complex interactions.
- Organoids as a Promising Bridge: Three-dimensional (3D) organoid cultures are emerging as a powerful tool, bridging the gap between high-throughput but low-clinical relevance 2D cell cultures and time-consuming, expensive animal models. They can better mimic tumor heterogeneity and microenvironment.
- Model Selection is Crucial: The choice of preclinical model is not one-size-fits-all. Different models are better suited for investigating specific aspects of PDT, such as vascular damage (CAM), immune response (syngeneic mice), or deep tumor penetration (rabbits, pigs).
Key Results
The review categorizes and analyzes seven main types of preclinical models used in PDT research:
- Chorioallantoic Membrane (CAM) Model: Useful for rapid assessment of PDT's effect on tumor vasculature due to its accessibility and ease of use, but limited by immune deficiency.
- Zebrafish Model: Offers high throughput, transparency for real-time imaging, and genetic similarities to humans, but has limitations in temperature control affecting tumor growth and a short observation period due to immune system maturation.
- Mouse Models (Xenograft and Syngeneic): Widely used due to short growth periods and genetic characteristics. Xenografts (human tumors in immunodeficient mice) are good for simulating human tumors, while syngeneic models (tumor cells and immunocompetent mice of the same strain) are crucial for studying anti-tumor immunity. However, both have limitations in mimicking the full complexity of human tumors and immune responses.
- Rat Model: Larger than mice, offering simpler anatomical structures for study and suitability for evaluating cardiovascular and metabolic systems, as well as various tumors.
- Rabbit Model: Possesses thicker skin and subcutaneous fat, mimicking human tumor depth better than rodents. In situ tumors in rabbits are more similar to human clinical neoplasms, making them valuable for studying deep-seated tumors.
- Pig Model: Anatomically and physiologically similar to humans, allowing for the use of similar catheters and equipment. However, establishing tumor models in pigs is challenging, limiting their widespread use.
- Organoid Model: 3D self-organizing structures derived from stem cells or tumor tissues, offering a more realistic representation of tumor heterogeneity, gene expression, and the tumor microenvironment. They are proving valuable for high-throughput drug screening and immune response studies.
Limitations and Future Work
The authors acknowledge that even the most advanced preclinical models have limitations. Traditional animal models, while extensively used, often fail to accurately predict clinical outcomes due to physiological differences and the complexity of the human tumor microenvironment. The paper suggests that while organoids offer a significant advancement, challenges remain in their cost, batch-to-batch variability, and the need for further development in integrating them with other technologies like organ-on-a-chip systems. Future work should focus on:
- Developing more sophisticated animal models: Models that better simulate the human tumor environment and its development are needed.
- Improving the translation of PDT model validation: Bridging the gap between preclinical results and clinical efficacy remains a critical challenge.
- Leveraging advanced technologies: Integrating organoid culture with organ-on-a-chip, 3D bioprinting, and gene editing technologies holds promise for creating more predictive and clinically relevant preclinical PDT models.
- Optimizing and simplifying models: The ultimate goal is to develop models that are not only accurate but also practical and cost-effective for widespread use in optimizing PDT strategies and promoting clinical application.
Summary updated